Clinical Trials Directory

Trials / Unknown

UnknownNCT01469936

Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia

Study of the Effect of the Food Supplement PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia (a Pilot, Double-blind, Randomized, Placebo-controlled Study)

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Lescuyer Laboratory · Industry
Sex
Female
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Fibromyalgia is a medical disorder characterized by chronic widespread pain, and a heightened and painful response to pressure. Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term fibromyalgia syndrome for the condition. Other symptoms include functional gastrointestinal pain and discomfort. The origin of these symptoms is not yet known, and a few hypotheses have been stated. One of the supposed mechanisms that may lead to gastrointestinal hypersensitivity is a chronic, low-grade, intestinal inflammation due to an increased intestinal permeability. In this study, we hypothesise that the food supplement PERMEAPROTECT (that contains, amongst other nutrients, glutamine and curcumin) contributes to reducing the intestinal permeability and low-grade inflammation, thus improving gastrointestinal quality of life.

Detailed description

Patients diagnosed with fibromyalgia will enter the study and follow a run-in phase during which they will all be supplemented with prebiotics, probiotics and grape fruit seed extract for 5 weeks : * Patients that do not present a satisfactory relief of gastrointestinal symptoms (patient subjective evaluation) will enter the randomised phase after 2 weeks +/- 1 week, at day D0. * Patients that do present a satisfactory relief of gastrointestinal symptoms (patient subjective evaluation) will exit the study at that point, and follow their usual medical care. Patients that enter the randomised phase will be supplemented with either PERMEAPROTECT or a PLACEBO, for 5 weeks +/- 1 week. Patients will then follow a 2 weeks +/- 1 week of wash-out, during which no supplementation will be made. Measures of the outcomes will be made : * at Day 0 (beginning of supplementation). * at Day 35 (+/- 7) (end of supplementation). * at Day 49 (+/- 7) (end of follow-up, end of study)

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPERMEAPROTECTComposition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid. Duration : 5 weeks +/- 1 week. Dosage : * First Week of intervention : 1/2 stick per day * Second to 5th Week : 1 stick per day
DIETARY_SUPPLEMENTPLACEBODuration : 5 weeks +/- 1 week. Dosage: * First Week : 1/2 stick per day * Second to 5th Week : 1 stick per day

Timeline

Start date
2011-11-01
Primary completion
2016-02-01
Completion
2016-12-01
First posted
2011-11-10
Last updated
2016-09-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT01469936. Inclusion in this directory is not an endorsement.